Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution
The search for effective pain treatments that are not addictive has been ongoing, especially with the prevalence of opioid addiction. The FDA recently released new guidelines to expand non-opioid options for chronic pain. However, the development of these drugs has faced challenges, as seen with Vertex Pharmaceuticals abandoning a next-generation non-opioid drug after a failed clinical trial. Acadia also faced a setback after a promising candidate failed a trial.
In the quest for non-opioid alternatives, cannabis has emerged as a potential basis for pain relief. Researchers at Washington University and Stanford found that a cannabis-derived compound effectively alleviated pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is at the forefront of developing a cannabinoid-based extract, known as Ver-01, for chronic pain treatment. Founder Clemens Fischer has invested over $250 million in this endeavor, aiming for approval in the EU and eventually the US. The drug has shown promising results in phase III trials, outperforming opioid painkillers with fewer side effects and no evidence of addiction.
Moving on to the realm of vaccines, the CDC’s immunization advisory committee, now under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., is set to discuss childhood vaccinations, including those for hepatitis B, measles, chickenpox, and COVID-19. Kennedy’s anti-vaccine views have raised concerns about the committee’s recommendations. There are fears that the committee may restrict COVID-19 vaccine recommendations to specific age groups and preexisting conditions, potentially impacting immunization policy in the US.
In the biotech and pharma sector, GSK announced a $30 billion investment in R&D and manufacturing facilities in the US over the next five years. This includes advancements in manufacturing and AI technologies for biopharma production. Additionally, Lilly revealed plans for a $5 billion manufacturing facility in Virginia. Krystal Biotech also received FDA approval for its topical gene therapy Vyjuvek for patients with dystrophic epidermolysis bullosa.
In the digital health and AI domain, the Mayo Clinic developed virtual clinical trials to predict the efficacy of potential heart failure treatments. Lila Sciences raised $235 million to bring AI to scientific research, enhancing data analysis and discovery processes.
On the public health front, a Harris poll revealed that over half of healthcare professionals plan to seek new job opportunities due to feeling undervalued by their employers. Investing in disease prevention and early detection could result in significant cost savings for the US healthcare system by 2040, according to a report from Deloitte.
These developments in the healthcare and pharmaceutical industries highlight the ongoing efforts to address pain management, vaccine policies, biotech advancements, digital health innovations, and public health challenges. Stay informed about the latest updates and trends in the healthcare landscape for a better understanding of the evolving healthcare ecosystem.
